TMCnet News
SafeHeal Appoints Dr. Karl Blohm as CEO to Prepare for Launch and CommercializationSafeHeal, an MD Start-ed company and a pioneer in the prevention of digestive surgery complications, today announced the appointment of Karl Blohm, Ph.D., as CEO. Anne Osdoit, co-founder of SafeHeal who has been CEO since the inception of SafeHeal, will remain involved as President of SafeHeal. Dr. Blohm was most recently Vice President International of GI Dynamics, an innovator in the field of endoscopically inserted treatments for management of type 2 diabetes and obesity, where he was instrumental in developing clinical evidence, physician support and market access pathways, securing the Endobarrier product launch in Europe and Middle East. He is a senior executive with more than 25 years of experience managing international business operations, combining capital equipment and medical devices in both large- and small-company environments. Dr. Blohm played a key role in successfully launching several innvative medical devices and technologies in his previous positions at Accuray, EndoGastric Solutions and Siemens (News - Alert), with particular focus on gastrointestinal surgical and endoscopic markets. Karl holds a Ph.D. in Elementary Particle Physics from the University of Paris. "MD Start builds companies on strong fundamentals - breakthrough technologies that really have value, focused on large, unaddressed clinical need, and significant market opportunity. SafeHeal is a great example of such high-impact therapy, which is essential to the development of the company," said Dr. Blohm. "I have been consistently impressed by the speed and quality of strategic planning and execution during the incubation of SafeHeal, with significant milestones already achieved, and a deep understanding of clinical endpoints relevant to patients, regulators and payers. The streamlined SafeHeal team has done a superb job bringing the technology from concept through preclinical validation, and I am thrilled to join the company to make its innovation available to patients around the world." "Karl is a perfect fit and brings a directly relevant experience to the company to move this technology successfully from the bench to the patient," said Anne Osdoit. "His network of clinicians, his knowledge of the regulatory and reimbursement processes and his expertise in bringing products to the market in the digestive field give us a unique opportunity to prepare for commercialization in Europe, the US and ultimately China, while continuing to advance our R&D and clinical validation programs. We are very excited to have him leading the company through the next phase of product launch." Click here for complete news release. View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005451/en/ |
